Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND ME...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Ramalingam, S, Blackhall, F, Krzakowski, M, Barrios, C, Park, K, Bover, I, Seog Heo, D, Rosell, R, Talbot, D, Frank, R, Letrent, S, Ruiz-Garcia, A, Taylor, I, Liang, J, Campbell, A, O'Connell, J, Boyer, M
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2012

Antzeko izenburuak

ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING
nork: Blackhall, F, et al.
Argitaratua: (2012)

Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
nork: Justin P Williams, et al.
Argitaratua: (2014-01-01)

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
nork: Ferdows Ather, et al.
Argitaratua: (2013-01-01)

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
nork: Jian Liu, et al.
Argitaratua: (2024-01-01)

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation
nork: Yujing Wang, et al.
Argitaratua: (2024-12-01)

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
nork: Petros D. Grivas, et al.
Argitaratua: (2013-10-01)

Tumor growth inhibition modeling to support the starting dose for dacomitinib
nork: Luke K. Fostvedt, et al.
Argitaratua: (2022-09-01)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
nork: George D. Wilson, et al.
Argitaratua: (2021-01-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
nork: Jinyao Zhang, et al.
Argitaratua: (2021-12-01)

Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats.
nork: Yukihiro Wada, et al.
Argitaratua: (2014-01-01)

Drug-induced liver injury associated with dacomitinib: A case report
nork: Xuanxuan Wang, et al.
Argitaratua: (2022-09-01)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
nork: Nawazish A. Khan, et al.
Argitaratua: (2014-07-01)

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
nork: Masahiro Iwasaku, et al.
Argitaratua: (2023-07-01)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
nork: Hisashi Tanaka, et al.
Argitaratua: (2022-05-01)

Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7.
nork: Felicity C Kalinowski, et al.
Argitaratua: (2012-01-01)

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
nork: Siavash Jabbari, et al.
Argitaratua: (2011-10-01)

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
nork: Abdul-Rahman Jazieh, et al.
Argitaratua: (2013-01-01)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
nork: Karachaliou N, et al.
Argitaratua: (2014-11-01)

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
nork: Raelene Endersby, et al.
Argitaratua: (2018-05-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression
nork: Nobutomo Ikarashi, et al.
Argitaratua: (2020-04-01)

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
nork: Jasmine G Lee, et al.
Argitaratua: (2012-01-01)

Erlotinib-induced dry eye
nork: Rashmita Ravisankar, et al.
Argitaratua: (2023-01-01)

Modified Synthesis of Erlotinib Hydrochloride
nork: Leila Barghi, et al.
Argitaratua: (2012-06-01)

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib
nork: Ana Ruiz-Garcia, et al.
Argitaratua: (2020-04-01)

A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
nork: Manal A. Alossaimi, et al.
Argitaratua: (2023-03-01)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
nork: Lavacchi D, et al.
Argitaratua: (2019-09-01)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
nork: Ayako Morita, et al.
Argitaratua: (2021-04-01)

Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy
nork: Kenneth K. Tanabe, et al.
Argitaratua: (2024-01-01)

Relativity and irreversibility
nork: I. Antoniou, et al.
Argitaratua: (2004-01-01)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
nork: Noem&iacute; Reguart, et al.
Argitaratua: (2010-06-01)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
nork: Bo Zhang, et al.
Argitaratua: (2022-03-01)

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report
nork: Lincer Robert, et al.
Argitaratua: (2010-10-01)

Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma
nork: Ailing Liu, et al.
Argitaratua: (2025-02-01)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
nork: Yibin Li, et al.
Argitaratua: (2022-08-01)

Stability and Formulation of Erlotinib in Skin Creams
nork: David Nguyen, et al.
Argitaratua: (2022-02-01)

Erlotinib-Induced Papulopustular Eruption and Mucositis
nork: Zehra Aşiran Serdar, et al.
Argitaratua: (2018-07-01)

Erlotinib in the treatment of advanced pancreatic cancer
nork: Robin K Kelley, et al.
Argitaratua: (2008-03-01)

Predicting Tumor Responses to Gefitinib and Erlotinib.
Argitaratua: (2005-01-01)

Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer
nork: Shun Mizusaki, et al.
Argitaratua: (2021-01-01)

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
nork: Ji Eun Shin, et al.
Argitaratua: (2025-02-01)